

Slovenia

Population 2019

2.1 million

Estimates of TB burden ^o , 2019	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	0.11 (0.096–0.13)	5.4 (4.6–6.3)
HIV-positive TB incidence	<0.01 (0–<0.01)	0.07 (0–0.28)
MDR/RR-TB incidence ^{oo}	0 (0–0)	0 (0–0)
HIV-negative TB mortality	<0.01 (<0.01–<0.01)	0.34 (0.33–0.34)
HIV-positive TB mortality	0 (0–<0.01)	0.01 (0–0.05)

Estimated proportion of TB cases with MDR/RR-TB, 2019

New cases	0% (0–4.6)
Previously treated cases	0% (0–60)

TB case notifications, 2019

Total new and relapse	98
- % tested with rapid diagnostics at time of diagnosis	86%
- % with known HIV status	74%
- % pulmonary	89%
- % bacteriologically confirmed ^{ooo}	93%
- % children aged 0–14 years	2%
- % women	36%
- % men	62%
Total cases notified	101

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2019	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2019	7% (6–7)

TB/HIV care in new and relapse TB patients, 2019

	Number	(%)
Patients with known HIV status who are HIV-positive	1	1%
- on antiretroviral therapy	1	100%

Drug-resistant TB care, 2019

% of bacteriologically confirmed TB cases tested for rifampicin resistance ^{ooo}	
- New cases	99%
- Previously treated cases	100%
Laboratory-confirmed cases*	MDR/RR-TB: 0, XDR-TB: 0
Patients started on treatment**	MDR/RR-TB: 0, XDR-TB: 0
MDR/RR-TB cases tested for resistance to second-line drugs	

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2018	78%	98
Previously treated cases, excluding relapse, registered in 2018	0%	1
HIV-positive TB cases registered in 2018		0
MDR/RR-TB cases started on second-line treatment in 2017		
XDR-TB cases started on second-line treatment in 2017		

TB preventive treatment, 2019

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100%

TB financing, 2020

National TB budget (US\$ millions)

^o Ranges represent uncertainty intervals

^{oo} MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


^{ooo} Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2019 and patients who were not laboratory-confirmed


-Draft- Tuberculosis profile

(Rate per 100 000 population per year)




Legend:
■ Total TB incidence
■ New and relapse TB cases notified
■ HIV-positive TB incidence

(Rate per 100 000 population per year)




Legend:
■ HIV-negative TB mortality

Notified cases by age group and sex, 2019



Legend:
■ Females
■ Males
 Incidence

Treatment success rate (%)



Legend:
■ New and relapse
■ Retreatment, excluding relapse
■ HIV-positive
■ MDR/RR-TB
■ XDR-TB